TrimRx's Blog
Mounjaro Gambling Addiction — What Patients Must Know
Mounjaro doesn’t cause gambling addiction — but GLP-1 medications may amplify compulsive behaviors in predisposed individuals. Here’s the evidence.
Zepbound Plateau 3 Months — Why Weight Loss Stalls | TrimRx
Zepbound plateau at 3 months happens when metabolic adaptation outpaces medication effect — typically 10–15% of patients experience this. Here’s how to
Build Muscle on Zepbound — Mechanisms and Strategies
Build muscle on Zepbound by prioritizing protein intake, resistance training, and leucine-rich meals — GLP-1 therapy doesn’t stop muscle growth.
Zepbound Plateau 6 Months — What’s Happening & What to Do
Weight loss stalls at 6 months on Zepbound are predictable, not failures. The GLP-1 receptor adaptation curve, not willpower, drives the plateau—here’s
Zepbound Strength Training — Muscle, Fat Loss, and Recomp
Zepbound (tirzepatide) alters protein synthesis signaling and recovery timing — here’s how to structure training, nutrition, and dose timing for muscle
Mounjaro Binge Eating — Does Tirzepatide Stop Binges?
Mounjaro reduces binge eating episodes by 60–70% in clinical observations through GLP-1 and GIP receptor agonism that normalizes hunger signaling.
Mounjaro 1 Month Weight Loss — Real Results & Timeline
Mounjaro produces 3-5% body weight loss in month one through dual GIP/GLP-1 action — slower than expected but clinically significant with proper titration.
Mounjaro Body Dysmorphia — Psychological Effects Explained
Mounjaro can trigger or worsen body dysmorphia through rapid weight loss and shifting self-perception. Understand the psychological risks and warning
Mounjaro Eating Disorder — Risk Factors & Safe Use
Mounjaro doesn’t cause eating disorders but can worsen existing patterns. Learn how GLP-1 therapy interacts with disordered eating and when it’s
